Clive Maund

Clive Maund has been president of, a successful resource sector website, since its inception in 2003. He has 30 years' experience in technical analysis and has worked for banks, commodity brokers and stockbrokers in the City of London. He holds a Diploma in Technical Analysis from the UK Society of Technical Analysts.

Recent Articles about Awakn Life Sciences Corp.

Biotech Co. An Attractive Investment 08/04/2023

Technical Analyst Clive Maund reviews Awakn Life Sciences Corp.'s 26-month and year-to-date charts to tell you why he believes it is an attractive investment.

Expert Says Life Science Co.'s Technical Setup Is 'Exceptionally Positive and Keeps Getting Better' 09/13/2022

Expert Clive Maund reviews the 6-month and 15-month charts for Awakn Life Sciences Corp. to explain why he thinks this company's technical setup is exceptionally positive.

Expert Says Life Science Corp.'s Technical Case Is Becoming Compelling 09/07/2022

Expert Clive Maund shares his view on Awakn Life Sciences Corp. as its stock continues to strengthen.

Biotech Co. To Receive 66% Funding From UK Gov. 08/17/2022

Expert Clive Maund reviews the latest update with Awakn Life Sciences Corp., including its recent rise in stock volume and the announcement that the company is to receive 66% funding support from the UK government for the development of its ketamine-assisted therapy treatment for alcohol use disorders.

Biotech Co. Awakes To Good News 08/06/2022

Awakn Life Sciences Corp.'s rating went to an Immediate Speculative Buy after it received substantial funding from the UK government. Expert Clive Maund shares his thoughts on the development.